Assistant Professor of Medicine, Assistant Professor of Oncology, Johns Hopkins University School of Medicine
Hematology
Dr. Michael A. McDevitt, MD
|
|
Give Review
Michael McDevitt works in the field of Hematology. He studied medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification". Michael A. McDevitt is also published. He has 63 publications published. The lastest publication: "A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.'
Publications
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT With high-dose posttransplantation cyclophosphamide.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic Leukemia cells in vitro.
- Recurrent genetic defects on chromosome 7q in Myeloid neoplasms.
- Burst-forming unit-erythroid assays to distinguish cellular bone marrow failure Disorders.
- Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in Myeloid malignancies.
- Somatic SETBP1 mutations in Myeloid malignancies.
- Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in Myeloid malignancies.
- Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic Leukemia but largely absent in juvenile myelomonocytic leu...
- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy With cytosine arabinoside and mitoxantrone for adults With newly diagnosed...
- Erythroid-Specific Transcriptional Changes in PBMCs from Pulmonary Hypertension Patients.
- Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed Acute myelogenous leukemia.
- Mutational spectrum analysis of chronic myelomonocytic Leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A.
- Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-Polycythemia vera myelofibrosis, but not essential thrombocytosis or polycy...
- 5-azacytidine as salvage treatment in relapsed Myeloid tumors after allogeneic bone marrow transplantation.
- Prognostic impact of SNP array karyotyping in myelodysplastic Syndromes and related myeloid malignancies.
- Large-Vessel Vasculitis As an Early Manifestation of Chronic Myelomonocytic Leukemia.
- KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for Acute leukemias.
- CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous Leukemia.
- Epigenetic differences in cytogenetically normal versus abnormal Acute myeloid leukemia.
- The Erg-onomics of myeloproliferation in Down Syndrome.
- PU.1 positively regulates GATA-1 expression in mast cells.
- Copy neutral loss of heterozygosity: a novel chromosomal lesion in Myeloid malignancies.
- Characterization of chromosome arm 20q abnormalities in Myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
- Lenalidomide-induced Acute interstitial nephritis.
- Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in Myeloid malignancies.
- Estimating platelet production in patients With HIV-related thrombocytopenia using the immature platelet fraction.
- New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in Acute myeloid leukemia.
- Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced Myeloid malignancies.
- Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.
- Loss of heterozygosity 4q24 and TET2 mutations Associated with myelodysplastic/myeloproliferative neoplasms.
- 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl,...
- Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan Anemia.
- Mast cell transcriptional networks.
- A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory Acute leukemias.
- Alterations of the HBP1 transcriptional repressor are associated with invasive breast Cancer.
- SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal Abnormalities in MDS/MPD-U and MPD.
- The HBP1 transcriptional repressor participates in RAS-induced premature senescence.
- A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial Anemia.
- Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.
- The Anemia of malaria infection: role of inflammatory cytokines.
- Acquired mutations in GATA1 in the megakaryoblastic Leukemia of Down syndrome.
- Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk Acute myelogenous leukemia.
- The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression.
- Mutations in GATA1 in both transient myeloproliferative disorder and Acute megakaryoblastic leukemia of Down syndrome.
- Role of allogeneic transplantation for FLT3/ITD Acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
- The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.
- Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of Leukemia patients: implications for occupational surveillance.
- Different sequence requirements for expression in erythroid and megakaryocytic cells Within a regulatory element upstream of the GATA-1 gene.
- A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.
- Transcription factor GATA-1 in megakaryocyte development.
- Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo.
- Novel homo- and hemizygous mutations in EZH2 in Myeloid malignancies.
- A "knockdown" mutation created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1.
- An upstream, DNase I hypersensitive region of the hematopoietic-expressed transcription factor GATA-1 gene confers developmental specificity in transgenic mice.
- TP53 mutations in Myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.
- Definition of essential sequences and functional equivalence of elements downstream of the adenovirus E2A and the early simian virus 40 polyadenylation sites.
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory Acute leukemias.
- Requirement of a downstream sequence for generation of a poly(A) addition site.
- Poly(A) site cleavage in a HeLa nuclear extract is dependent on downstream sequences.
Schools
Weill Cornell Medical College
Johns Hopkins Hospital
Brigham and Women39s Hospital
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
Johns Hopkins University -
Weill Cornell Medical College of Cornell University
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1629027347 | |
| NPPES Provider LastName | MCDEVITT | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 66.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629027347 |
| Last Name Of The Provider | MCDEVITT |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Michael Auerbach, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Donegan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lavanya Yarlagadda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry Waterbury, MD |
|
|
Dr. John R. Hess, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Doha M. Itani, MD |
|
|
Dr. Jenny Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles S. Hesdorffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip A. Dennis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheetal Karne, MD |
|
|
Dr. Gabrielle T. Prince, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Adrian G. Murphy, MB CHB |
|
|
Hibba-Tul Rehman, MB BS |
|
|
Dr. Michael T. Schweizer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lukasz P. Gondek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jian L. Campian, MD |